Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity

被引：20

作者：

Ayza, Muluken Altaye ^{[1
]}

Zewdie, Kaleab Alemayehu ^{[1
]}

Tesfaye, Bekalu Amare ^{[1
]}

Gebrekirstos, Selamawit Tesfamariam ^{[1
]}

Berhe, Derbew Fikadu ^{[1
]}

机构：

[1] Mekelle Univ, Sch Pharm, Dept Pharmacol & Toxicol, Mekelle, Ethiopia

来源：

DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY | 2020年 / 13卷

关键词：

diabetes mellitus; hypertension; peroxisome proliferator-activated receptors; telmisartan; PROLIFERATOR-ACTIVATED-RECEPTOR; TYPE-2; DIABETES-MELLITUS; IMPROVES INSULIN-RESISTANCE; PEROXISOME-PROLIFERATOR; ENDOTHELIAL FUNCTION; GLUCOSE-UPTAKE; MANAGEMENT; ROSIGLITAZONE; HYPERTENSION; PIOGLITAZONE;

D O I：

10.2147/DMSO.S265399

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Telmisartan is an angiotensin II receptor antagonist, which selectively inhibits the angiotensin II type 1 receptor. Thus, it is widely used for hypertension management. Nowadays, telmisartan's effect on peroxisome proliferator-activated receptors (PPARs) is gaining wider attention. PPARs are ligand-activated transcription factors that belong to the nuclear hormone receptor superfamily. Telmisartan is reported to have a partial PPAR gamma-agonistic effect while avoiding the safety concerns found with full PPAR gamma agonists (thiazolidinediones). Telmisartan could be an alternative treatment option, with dual benefit for diabetes mellitus (DM) and hypertension. This review summarizes the anti-diabetic activity of telmisartan via its partial PPAR gamma-agonistic activity.

引用

页码：3627 / 3635

页数：9

共 96 条

[1] Balaglitazone: A Second Generation Peroxisome Proliferator-Activated Receptor (PPAR) Gamma (γ) Agonist [J].

Agrawal, R. ;

Jain, P. ;

Dikshit, S. N. .

MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2012, 12 (02) :87-97

[2]

Al-Hammami FA, 2012, RAF J SCI, V23, P34

[3] Updates on Managing Type 2 Diabetes Mellitus with Natural Products: Towards Antidiabetic Drug Development [J].

Alam, Fahmida ;

Islam, Md. Asiful ;

Kamal, Mohammad Amjad ;

Gan, Siew Hua .

CURRENT MEDICINAL CHEMISTRY, 2018, 25 (39) :5395-5431

[4] Structural basis for telmisartan-mediated partial activation of PPAR gamma [J].

Amano, Yasushi ;

Yamaguchi, Tomohiko ;

Ohno, Kazuki ;

Niimi, Tatsuya ;

Orita, Masaya ;

Sakashita, Hitoshi ;

Takeuchi, Makoto .

HYPERTENSION RESEARCH, 2012, 35 (07) :715-719

[5] GQ-16, a Novel Peroxisome Proliferator-activated Receptor γ (PPARγ) Ligand, Promotes Insulin Sensitization without Weight Gain [J].

Amato, Angelica A. ;

Rajagopalan, Senapathy ;

Lin, Jean Z. ;

Carvalho, Bruno M. ;

Figueira, Ana C. M. ;

Lu, Jenny ;

Ayers, Stephen D. ;

Mottin, Melina ;

Silveira, Rodrigo L. ;

Souza, Paulo C. T. ;

Mourao, Rosa H. V. ;

Saad, Mario J. A. ;

Togashi, Marie ;

Simeoni, Luiz A. ;

Abdalla, Dulcineia S. P. ;

Skaf, Munir S. ;

Polikparpov, Igor ;

Lima, Maria C. A. ;

Galdino, Suely L. ;

Brennan, Richard G. ;

Baxter, John D. ;

Pitta, Ivan R. ;

Webb, Paul ;

Phillips, Kevin J. ;

Neves, Francisco A. R. .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (33) :28169-28179

[6]

AMOGHIMATH S, 2019, BIOMED PHARMACOL J, V12, P1303, DOI DOI 10.13005/bpj/1758

[7] Submaximal PPARγ activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders [J].

Balakumar, Pitchai ;

Kathuria, Sonam .

BRITISH JOURNAL OF PHARMACOLOGY, 2012, 166 (07) :1981-1992

[8] Preventing renal complications in type 2 diabetes: Results of the diabetics exposed to Telmisartan and enalapril trial [J].

Barnett, Anthony .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (04) :S132-S135

[9] Effects of Telmisartan on Glucose Levels in People at High Risk for Cardiovascular Disease but Free From Diabetes The TRANSCEND study [J].

Barzilay, Joshua I. ;

Gao, Peggy ;

Ryden, Lars ;

Schumacher, Helmut ;

Probstfield, Jeffrey ;

Commerford, Patrick ;

Dans, Antonio ;

Ferreira, Rafael ;

Keltai, Matyas ;

Paolasso, Ernesto ;

Yusuf, Salim ;

Teo, Koon .

DIABETES CARE, 2011, 34 (09) :1902-1907

[10] Telmisartan - A review of its use in the management of hypertension [J].

Battershill, AJ ;

Scott, LJ .

DRUGS, 2006, 66 (01) :51-83

← 1 2 3 4 5 6 7 8 9 10 →